Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD PRATLEY

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1194837476
CMS profile
767675
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$131,947.26

112 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk AS $47,593.40 19
Lilly USA, LLC $22,767.93 26
Corcept Therapeutics $20,140.22 20
Boehringer Ingelheim Pharmaceuticals, Inc. $9,887.77 11
Bayer Healthcare Pharmaceuticals Inc. $8,714.17 15
ABBVIE INC. $7,150.00 1
Novo Nordisk Inc $6,595.69 8
Amgen Inc. $4,665.46 2
Eli Lilly and Company $2,100.00 1
Lexicon Pharmaceuticals, Inc. $1,208.70 7
PFIZER INC. $1,000.00 1
Abbott Laboratories $123.92 1

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD PRATLEY

NPI 1194837476 · CMS profile ID 767675

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194837476?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD PRATLEY, NPI 1194837476, CMS profile ID 767675. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194837476?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RICHARD PRATLEY, NPI 1194837476, CMS profile ID 767675. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194837476?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RICHARD PRATLEY, NPI 1194837476, CMS profile ID 767675, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1194837476?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

112 matching records · $131,947.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 112 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 112.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Corcept Therapeutics $3,262.5007/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779721 CMS
Lilly USA, LLC $1,050.0007/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135376678 CMS
Bayer Healthcare Pharmaceuticals Inc. $37.2806/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086078526 CMS
Bayer Healthcare Pharmaceuticals Inc. $357.9206/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086078536 CMS
Bayer Healthcare Pharmaceuticals Inc. $70.9006/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086233390 CMS
Bayer Healthcare Pharmaceuticals Inc. $50.4006/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086259262 CMS
Corcept Therapeutics $10.4506/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779723 CMS
Corcept Therapeutics $357.9206/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779725 CMS
Corcept Therapeutics $37.2806/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779727 CMS
Corcept Therapeutics $124.0106/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779729 CMS
Corcept Therapeutics $49.9606/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779775 CMS
Novo Nordisk Inc $123.6006/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097633189 CMS
Lilly USA, LLC $2,100.0005/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135364679 CMS
Corcept Therapeutics $29.1005/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779765 CMS
Corcept Therapeutics $476.9605/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779771 CMS
Novo Nordisk AS $2,762.5005/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096553299 CMS
ABBVIE INC. $7,150.0005/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105308457 CMS
Lilly USA, LLC $2,100.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135357283 CMS
Lilly USA, LLC $800.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135357285 CMS
Corcept Therapeutics $3,772.0004/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779767 CMS
Bayer Healthcare Pharmaceuticals Inc. $7,000.0004/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086239004 CMS
Lilly USA, LLC $800.0004/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135364681 CMS
Lilly USA, LLC $2,100.0004/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135386919 CMS
Novo Nordisk Inc $1,986.8804/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097332658 CMS
Lilly USA, LLC $1,050.0003/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135366026 CMS
Lilly USA, LLC $1,050.0003/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135334439 CMS
Corcept Therapeutics $49.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779745 CMS
Corcept Therapeutics $24.8903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779747 CMS
Corcept Therapeutics $49.9803/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779749 CMS
Corcept Therapeutics $49.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779751 CMS
Corcept Therapeutics $24.8903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779753 CMS
Corcept Therapeutics $637.2003/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779743 CMS
Bayer Healthcare Pharmaceuticals Inc. $564.8103/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086080926 CMS
Bayer Healthcare Pharmaceuticals Inc. $32.0003/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086155264 CMS
Bayer Healthcare Pharmaceuticals Inc. $33.0303/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086174140 CMS
Bayer Healthcare Pharmaceuticals Inc. $95.4803/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086235630 CMS
Bayer Healthcare Pharmaceuticals Inc. $50.0003/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086235632 CMS
Bayer Healthcare Pharmaceuticals Inc. $33.0303/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086258272 CMS
Bayer Healthcare Pharmaceuticals Inc. $53.2503/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086080666 CMS
Bayer Healthcare Pharmaceuticals Inc. $206.5003/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086080986 CMS
Bayer Healthcare Pharmaceuticals Inc. $24.5503/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086155268 CMS
Bayer Healthcare Pharmaceuticals Inc. $105.0203/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086174142 CMS
Lilly USA, LLC $1,050.0003/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135376676 CMS
Corcept Therapeutics $6,815.0003/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117779741 CMS
Lilly USA, LLC $1,050.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135357281 CMS
Lilly USA, LLC $2,100.0002/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135386915 CMS
Lilly USA, LLC $800.0002/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135386917 CMS
Lilly USA, LLC $5,250.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135353720 CMS
Lilly USA, LLC $35.0001/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135376666 CMS
Lilly USA, LLC $8.6501/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135376668 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $149,500.92 89
PY2020 $57,592.99 31
PY2021 $47,289.22 24
PY2022 $23,988.61 12
PY2023 $52,419.17 28
PY2024 $131,947.26 112
PY2025 $272,743.24 168

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $8,218,704.22 614
PY2024 Recipient $10,200.00 4
PY2024 Principal investigator $64,459.94 33
PY2023 Recipient $1,900.00 1
PY2023 Principal investigator $54,411.09 29
PY2022 Recipient $28,462.26 23
PY2022 Principal investigator $38,153.62 79
PY2021 Recipient $24,170.00 24
PY2021 Principal investigator $27,626.75 50
PY2020 Recipient $17,297.50 10
PY2020 Principal investigator $19,498.84 50
PY2019 Recipient $4,069.08 8
PY2019 Principal investigator $49,784.98 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

614 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 12/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994659
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 12/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994661
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633155
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633159
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633169
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633171
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633173
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633181
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633183
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633187
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633189
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633195
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633199
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633201
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633203
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633215
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633219
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633221
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633223
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633227
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633231
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633233
Principal investigator 1 Boehringer Ingelheim International GmbH $3,073.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633237
Principal investigator 1 Boehringer Ingelheim International GmbH $5,375.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633239
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633241
Principal investigator 1 Boehringer Ingelheim International GmbH $5,486.40 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633247
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633249
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633251
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633255
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633259
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633261
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633263
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633267
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633271
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633279
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633283
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633287
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633293
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633295
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633301
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633303
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633305
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633313
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633323
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633327
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633331
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633337
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633345
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633347
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633353
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633355
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633357
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633363
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633365
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633367
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633373
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633381
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633383
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633385
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633387
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633389
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633401
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633407
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633411
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633413
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633415
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633417
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633419
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633427
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633429
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633433
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633435
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633437
Principal investigator 1 Boehringer Ingelheim International GmbH $5,486.40 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633439
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633443
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633453
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633457
Principal investigator 1 Boehringer Ingelheim International GmbH $6,381.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633459
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633461
Principal investigator 1 Boehringer Ingelheim International GmbH $4,704.75 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633467
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633471
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633475
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633479
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633481
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633485
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633487
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633489
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633491
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633501
Principal investigator 1 Boehringer Ingelheim International GmbH $13,178.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633503
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633505
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633507
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633513
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633517
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633519
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633523
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633527
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633529
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633531
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633535
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633537
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633543
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633545
Principal investigator 1 Boehringer Ingelheim International GmbH $6,381.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633547
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633555
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633559
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633561
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633565
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633571
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633579
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633581
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633583
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633597
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633599
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633603
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633607
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633611
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633617
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633619
Principal investigator 1 Boehringer Ingelheim International GmbH $6,043.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633621
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633623
Principal investigator 1 Boehringer Ingelheim International GmbH $5,686.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633627
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633629
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633631
Principal investigator 1 Boehringer Ingelheim International GmbH $5,459.40 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633635
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633641
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633643
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633651
Principal investigator 1 Boehringer Ingelheim International GmbH $6,043.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633655
Principal investigator 1 Boehringer Ingelheim International GmbH $3,073.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633659
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633665
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633667
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633669
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633673
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633675
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633679
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633683
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633685
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633693
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633695
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633701
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633709
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633713
Principal investigator 1 Boehringer Ingelheim International GmbH $5,103.00 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633715
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633717
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633719
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633725
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633727
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633729
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633731
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633733
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633737
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633747
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633753
Principal investigator 1 Boehringer Ingelheim International GmbH $10,219.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633755
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633757
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633759
Principal investigator 1 Boehringer Ingelheim International GmbH $6,381.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633761
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633763
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633769
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633771
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633775
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633781
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633783
Principal investigator 1 Boehringer Ingelheim International GmbH $3,073.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633791
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633795
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633797
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633801
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633805
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633809
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633813
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633815
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633817
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633821
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633829
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633833
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633835
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633839
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633843
Principal investigator 1 Boehringer Ingelheim International GmbH $6,043.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633845
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633847
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633849
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633853
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633855
Principal investigator 1 Boehringer Ingelheim International GmbH $5,486.40 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633859
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633861
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633865
Principal investigator 1 Boehringer Ingelheim International GmbH $3,073.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633873
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633875
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633877
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633881
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633885
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633887
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633891
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633893
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633895
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633899
Principal investigator 1 Boehringer Ingelheim International GmbH $13,212.45 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633909
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633913
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633921
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633925
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633929
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633961
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633963
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633965
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633967
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633969
Principal investigator 1 Boehringer Ingelheim International GmbH $1,109.68 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633971
Principal investigator 1 Boehringer Ingelheim International GmbH $13.50 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633973
Principal investigator 1 Boehringer Ingelheim International GmbH $84.00 12/17/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633975
Principal investigator 1 Boehringer Ingelheim International GmbH $13,212.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633157
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633161
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633163
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633165
Principal investigator 1 Boehringer Ingelheim International GmbH $5,085.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633167
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633175
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633177
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633179
Principal investigator 1 Boehringer Ingelheim International GmbH $6,381.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633185
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633191
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633193
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633197
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633205
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633207
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633209
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633211
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633213
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633217
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633225
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633229
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633235
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633243
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633245
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633253
Principal investigator 1 Boehringer Ingelheim International GmbH $5,375.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633257
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633265
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633269
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633273
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633275
Principal investigator 1 Boehringer Ingelheim International GmbH $13,178.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633277
Principal investigator 1 Boehringer Ingelheim International GmbH $5,486.40 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633281
Principal investigator 1 Boehringer Ingelheim International GmbH $5,085.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633285
Principal investigator 1 Boehringer Ingelheim International GmbH $3,073.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633289
Principal investigator 1 Boehringer Ingelheim International GmbH $13,212.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633291
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633297
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633299
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633307
Principal investigator 1 Boehringer Ingelheim International GmbH $13,178.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633309
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633311
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633315
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633317
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633319
Principal investigator 1 Boehringer Ingelheim International GmbH $4,791.15 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633321
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633325
Principal investigator 1 Boehringer Ingelheim International GmbH $5,686.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633329
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633333
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633335
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633339
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633341
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633343
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633349
Principal investigator 1 Boehringer Ingelheim International GmbH $4,704.75 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633351
Principal investigator 1 Boehringer Ingelheim International GmbH $10,219.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633359
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633361
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633369
Principal investigator 1 Boehringer Ingelheim International GmbH $5,103.00 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633371
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633375
Principal investigator 1 Boehringer Ingelheim International GmbH $13,212.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633377
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633379
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633391
Principal investigator 1 Boehringer Ingelheim International GmbH $4,704.75 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633393
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633395
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633397
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633399
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633403
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633405
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633409
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633421
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633423
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633425
Principal investigator 1 Boehringer Ingelheim International GmbH $4,704.75 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633431
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633441
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633445
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633447
Principal investigator 1 Boehringer Ingelheim International GmbH $6,043.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633449
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633451
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633455
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633463
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633465
Principal investigator 1 Boehringer Ingelheim International GmbH $4,720.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633469
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633473
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633477
Principal investigator 1 Boehringer Ingelheim International GmbH $5,486.40 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633483
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633493
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633495
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633497
Principal investigator 1 Boehringer Ingelheim International GmbH $5,402.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633499
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633509
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633511
Principal investigator 1 Boehringer Ingelheim International GmbH $6,381.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633515
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633521
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633525
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633533
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633539
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633541
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633549
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633551
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633553
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633557
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633563
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633567
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633569
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633573
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633575
Principal investigator 1 Boehringer Ingelheim International GmbH $6,381.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633577
Principal investigator 1 Boehringer Ingelheim International GmbH $5,375.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633585
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633587
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633589
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633591
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633593
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633595
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633601
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633605
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633609
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633613
Principal investigator 1 Boehringer Ingelheim International GmbH $5,476.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633615
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633625
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633633
Principal investigator 1 Boehringer Ingelheim International GmbH $3,073.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633637
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633639
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633645
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633647
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633649
Principal investigator 1 Boehringer Ingelheim International GmbH $5,375.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633653
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633657
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633661
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633663
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633671
Principal investigator 1 Boehringer Ingelheim International GmbH $6,043.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633677
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633681
Principal investigator 1 Boehringer Ingelheim International GmbH $5,476.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633687
Principal investigator 1 Boehringer Ingelheim International GmbH $10,219.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633689
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633691
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633697
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633699
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633703
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633705
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633707
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633711
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633721
Principal investigator 1 Boehringer Ingelheim International GmbH $6,381.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633723
Principal investigator 1 Boehringer Ingelheim International GmbH $3,073.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633735
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633739
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633741
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633743
Principal investigator 1 Boehringer Ingelheim International GmbH $5,686.20 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633745
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633749
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633751
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633765
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633767
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633773
Principal investigator 1 Boehringer Ingelheim International GmbH $5,503.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633777
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633779
Principal investigator 1 Boehringer Ingelheim International GmbH $12,908.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633785
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633787
Principal investigator 1 Boehringer Ingelheim International GmbH $4,791.15 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633789
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633793
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633799
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633803
Principal investigator 1 Boehringer Ingelheim International GmbH $13,178.70 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633807
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633811
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633819
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633823
Principal investigator 1 Boehringer Ingelheim International GmbH $4,637.25 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633825
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633827
Principal investigator 1 Boehringer Ingelheim International GmbH $9,814.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633831
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633837
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633841
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633851
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633857
Principal investigator 1 Boehringer Ingelheim International GmbH $10,219.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633863
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633867
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633869
Principal investigator 1 Boehringer Ingelheim International GmbH $12,874.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633871
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633879
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633883
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633889
Principal investigator 1 Boehringer Ingelheim International GmbH $5,598.45 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633897
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633901
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633903
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633905
Principal investigator 1 Boehringer Ingelheim International GmbH $3,091.50 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633907
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633911
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633915
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633917
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633919
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633923
Principal investigator 1 Boehringer Ingelheim International GmbH $6,043.95 12/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633927
Principal investigator 1 GENZYME CORPORATION $2,760.00 12/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Dose-finding study vs Placebo in children, adolescents and young adults (6-21yo) with T1D No dispute reported 06/30/2026 1226142002
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 12/09/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994653
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 12/09/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994655
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 12/09/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994657
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 12/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994649
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 12/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994651
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,263.60 12/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248395844
Principal investigator 1 Dompe Farmaceutici S.p.A. $7,694.00 12/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248395848
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 12/01/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994647
Principal investigator 1 Boehringer Ingelheim International GmbH $7,616.00 11/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633153
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633151
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 11/20/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994639
Principal investigator 1 Boehringer Ingelheim International GmbH $9.80 11/19/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633949
Principal investigator 1 Boehringer Ingelheim International GmbH $128.26 11/19/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633951
Principal investigator 1 Boehringer Ingelheim International GmbH $912.50 11/19/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633953
Principal investigator 1 Boehringer Ingelheim International GmbH $160.08 11/19/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633955
Principal investigator 1 Boehringer Ingelheim International GmbH $26.50 11/19/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633957
Principal investigator 1 Boehringer Ingelheim International GmbH $63.00 11/19/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633959
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 11/14/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994645
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 11/06/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994641
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 11/06/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994643
Principal investigator 1 Boehringer Ingelheim International GmbH $5.60 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633931
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633933
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633935
Principal investigator 1 Boehringer Ingelheim International GmbH $1,642.50 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633937
Principal investigator 1 Boehringer Ingelheim International GmbH $11.10 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633939
Principal investigator 1 Boehringer Ingelheim International GmbH $9.16 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633941
Principal investigator 1 Boehringer Ingelheim International GmbH $194.88 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633943
Principal investigator 1 Boehringer Ingelheim International GmbH $16.00 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633945
Principal investigator 1 Boehringer Ingelheim International GmbH $52.50 10/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633947
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 10/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994633
Principal investigator 1 Boehringer Ingelheim International GmbH $446.45 10/22/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633149
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 10/14/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994629
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 10/14/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994631
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.66 10/13/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994637
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 10/09/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994625
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,537.88 10/09/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994627
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 10/06/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994623
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 10/03/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994635
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 09/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994609
Principal investigator 1 Boehringer Ingelheim International GmbH $803.00 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633115
Principal investigator 1 Boehringer Ingelheim International GmbH $1.85 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633117
Principal investigator 1 Boehringer Ingelheim International GmbH $9.16 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633119
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633121
Principal investigator 1 Boehringer Ingelheim International GmbH $1,261.00 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633123
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633125
Principal investigator 1 Boehringer Ingelheim International GmbH $18.00 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633127
Principal investigator 1 Boehringer Ingelheim International GmbH $15.75 09/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633129
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 09/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994607
Principal investigator 1 Boehringer Ingelheim International GmbH $11.00 09/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633135
Principal investigator 1 Boehringer Ingelheim International GmbH $67.65 09/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633137
Principal investigator 1 Boehringer Ingelheim International GmbH $25.80 09/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633139
Principal investigator 1 Boehringer Ingelheim International GmbH $28.32 09/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633141
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 09/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633143
Principal investigator 1 Boehringer Ingelheim International GmbH $236.25 09/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633145
Principal investigator 1 Boehringer Ingelheim International GmbH $62.48 09/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633147
Principal investigator 1 Boehringer Ingelheim International GmbH $1.00 09/04/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633131
Principal investigator 1 Boehringer Ingelheim International GmbH $6.15 09/04/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633133
Principal investigator 1 Boehringer Ingelheim International GmbH $21.00 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633097
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633099
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633101
Principal investigator 1 Boehringer Ingelheim International GmbH $2,847.00 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633103
Principal investigator 1 Boehringer Ingelheim International GmbH $5.92 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633105
Principal investigator 1 Boehringer Ingelheim International GmbH $559.12 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633107
Principal investigator 1 Boehringer Ingelheim International GmbH $403.52 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633109
Principal investigator 1 Boehringer Ingelheim International GmbH $58.50 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633111
Principal investigator 1 Boehringer Ingelheim International GmbH $199.50 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633113
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 08/26/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994605
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 08/19/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994599
Principal investigator 1 GENZYME CORPORATION $750.00 08/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Dose-finding study vs Placebo in children, adolescents and young adults (6-21yo) with T1D No dispute reported 06/30/2026 1226141862
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 08/15/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994601
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 08/15/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994603
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 08/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994597
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 07/31/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994615
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 07/31/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994621
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633081
Principal investigator 1 Boehringer Ingelheim International GmbH $128.26 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633083
Principal investigator 1 Boehringer Ingelheim International GmbH $1,423.50 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633085
Principal investigator 1 Boehringer Ingelheim International GmbH $2.59 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633087
Principal investigator 1 Boehringer Ingelheim International GmbH $183.28 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633089
Principal investigator 1 Boehringer Ingelheim International GmbH $605.28 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633091
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633093
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 07/28/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633095
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,415.00 07/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248395842
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,958.55 07/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248395846
Principal investigator 1 GENZYME CORPORATION $30,292.00 07/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Dose-finding study vs Placebo in children, adolescents and young adults (6-21yo) with T1D No dispute reported 06/30/2026 1226141844
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 07/16/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994613
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 07/07/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994611
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 07/07/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994617
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,075.78 07/07/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994619
Principal investigator 1 Boehringer Ingelheim International GmbH $3,026.70 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632891
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632893
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632895
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632903
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632905
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632909
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632911
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632915
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632917
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632919
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632921
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632927
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632929
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632931
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632935
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632937
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632941
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632957
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632963
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632981
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632983
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632985
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632993
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.25 06/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632995
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633061
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633063
Principal investigator 1 Boehringer Ingelheim International GmbH $876.00 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633065
Principal investigator 1 Boehringer Ingelheim International GmbH $5.18 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633067
Principal investigator 1 Boehringer Ingelheim International GmbH $9.16 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633069
Principal investigator 1 Boehringer Ingelheim International GmbH $171.68 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633071
Principal investigator 1 Boehringer Ingelheim International GmbH $529.62 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633073
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633075
Principal investigator 1 Boehringer Ingelheim International GmbH $33.00 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633077
Principal investigator 1 Boehringer Ingelheim International GmbH $73.50 06/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633079
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632897
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632899
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632901
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632907
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632913
Principal investigator 1 Boehringer Ingelheim International GmbH $13,402.00 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632933
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632939
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.25 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632943
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632945
Principal investigator 1 Boehringer Ingelheim International GmbH $4,500.00 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632947
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632949
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632951
Principal investigator 1 Boehringer Ingelheim International GmbH $8,271.45 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632953
Principal investigator 1 Boehringer Ingelheim International GmbH $5,227.20 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632955
Principal investigator 1 Boehringer Ingelheim International GmbH $6,138.45 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632959
Principal investigator 1 Boehringer Ingelheim International GmbH $3,026.70 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632961
Principal investigator 1 Boehringer Ingelheim International GmbH $6,138.45 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632965
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632967
Principal investigator 1 Boehringer Ingelheim International GmbH $3,026.70 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632969
Principal investigator 1 Boehringer Ingelheim International GmbH $6,138.45 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632971
Principal investigator 1 Boehringer Ingelheim International GmbH $6,604.20 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632973
Principal investigator 1 Boehringer Ingelheim International GmbH $6,604.20 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632975
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632977
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632979
Principal investigator 1 Boehringer Ingelheim International GmbH $6,604.20 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632987
Principal investigator 1 Boehringer Ingelheim International GmbH $6,138.45 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632989
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.25 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632991
Principal investigator 1 Boehringer Ingelheim International GmbH $169,240.00 06/23/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632997
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 06/11/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994595
Principal investigator 1 Boehringer Ingelheim International GmbH $316.20 06/09/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632925
Principal investigator 1 Boehringer Ingelheim International GmbH $1,071.48 06/05/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632923
Principal investigator 1 Boehringer Ingelheim International GmbH $25.68 05/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633027
Principal investigator 1 Boehringer Ingelheim International GmbH $34.32 05/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633029
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 05/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633031
Principal investigator 1 Boehringer Ingelheim International GmbH $73.80 05/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633033
Principal investigator 1 Boehringer Ingelheim International GmbH $958.08 05/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633035
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 05/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994593
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632999
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633001
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633003
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633005
Principal investigator 1 Boehringer Ingelheim International GmbH $6,138.45 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633007
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633009
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633011
Principal investigator 1 Boehringer Ingelheim International GmbH $6,138.45 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633013
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633015
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633017
Principal investigator 1 Boehringer Ingelheim International GmbH $2,751.30 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633019
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633021
Principal investigator 1 Boehringer Ingelheim International GmbH $8,253.90 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633023
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633025
Principal investigator 1 Boehringer Ingelheim International GmbH $6,138.45 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633037
Principal investigator 1 Boehringer Ingelheim International GmbH $3,026.70 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633039
Principal investigator 1 Boehringer Ingelheim International GmbH $732.38 05/29/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633041
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633043
Principal investigator 1 Boehringer Ingelheim International GmbH $163.24 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633045
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633047
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633049
Principal investigator 1 Boehringer Ingelheim International GmbH $4.07 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633051
Principal investigator 1 Boehringer Ingelheim International GmbH $102.08 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633053
Principal investigator 1 Boehringer Ingelheim International GmbH $2.52 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633055
Principal investigator 1 Boehringer Ingelheim International GmbH $21.00 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633057
Principal investigator 1 Boehringer Ingelheim International GmbH $110.25 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220633059
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 05/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994591
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 05/15/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994589
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 04/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994583
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 04/30/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994587
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 04/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994581
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,613.64 04/24/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220994585
Principal investigator 1 Eli Lilly and Company $5,717,828.94 04/23/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A RANDOMIZED, DOUBLE-BLIND, PHASE 1 STUDY TO INVESTIGATE THE EFFECT OF LY3437943 VERSUS PLACEBO ON CALORIE INTAKE AND ENERGY EXPENDITURE IN PARTICIPANTS WITH OBESITY UNDER CALORIE RESTRICTION No dispute reported 06/30/2026 1187871471
Principal investigator 1 Dompe Farmaceutici S.p.A. $858.80 04/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248395850
Principal investigator 1 Novo Nordisk AS $3,122.82 03/31/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
EX9924-4473 No dispute reported 06/30/2026 1213722660
Principal investigator 1 AstraZeneca Pharmaceuticals LP $98,639.30 03/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185551519
Principal investigator 1 Boehringer Ingelheim International GmbH $25.68 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632857
Principal investigator 1 Boehringer Ingelheim International GmbH $34.32 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632859
Principal investigator 1 Boehringer Ingelheim International GmbH $25.72 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632861
Principal investigator 1 Boehringer Ingelheim International GmbH $22.08 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632863
Principal investigator 1 Boehringer Ingelheim International GmbH $1,071.48 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632865
Principal investigator 1 Boehringer Ingelheim International GmbH $55.80 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632867
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632869
Principal investigator 1 Boehringer Ingelheim International GmbH $73.80 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632871
Principal investigator 1 Boehringer Ingelheim International GmbH $958.08 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632873
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 03/10/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632875
Principal investigator 1 Novo Nordisk AS $1,200.00 01/31/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
EX9924-4473 No dispute reported 06/30/2026 1213796498
Principal investigator 1 Boehringer Ingelheim International GmbH $9.80 01/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632877
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 01/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632879
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 01/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632881
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 01/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632883
Principal investigator 1 Boehringer Ingelheim International GmbH $1.85 01/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632885
Principal investigator 1 Boehringer Ingelheim International GmbH $88.16 01/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632887
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 01/27/2025 Non-covered Recipient Entity
Adventhealth Research Institute-Translational Research Institute Department
Open-label, randomised, 2 parallel-group, Phase I trial An active-comparator-controlled, open-label study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity No dispute reported 06/30/2026 1220632889
Principal investigator 1 Eli Lilly and Company $7,735.60 01/03/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A RANDOMIZED, DOUBLE-BLIND, PHASE 1 STUDY TO INVESTIGATE THE EFFECT OF LY3437943 VERSUS PLACEBO ON CALORIE INTAKE AND ENERGY EXPENDITURE IN PARTICIPANTS WITH OBESITY UNDER CALORIE RESTRICTION No dispute reported 06/30/2026 1187877317